569 7. Oltre il Trapianto disease: results from phase I/II trial. Mol. Ther. 2011 Nov;19(11):2092101. doi: 10.1038/mt.2011.166 [35] Stein S, Ott MG, Schultze-Strasser S, Jauch A, Burwinkel B, Kinner A, et al. Genomic instability and myelodysplasia with monosomy 7 consequent to EVI1 activation after gene therapy for chronic granulomatous disease. Nat. Med. 2010 Feb;16(2):198-204. doi: 10.1038/nm.2088. [36] Kohn DB, Booth C, Kang EM, Pai SY, Shaw KL, Santilli G, et al.; Net4CGD consortium. Lentiviral gene therapy for X-linked chronic granulomatous disease. Nat. Med. 2020 Feb;26(2):200-206. doi: 10.1038/s41591-019-0735-5 [37] Taher AT, Musallam KM, Cappellini MD. beta-Thalassemias. N Engl J Med 2021;384(8):727-43. doi: 10.1056/NEJMra2021838 [38] Kato GJ, Piel FB, Reid CD, Gaston MH, Ohene-Frempong K, Krishnamurti L, et al. Sickle cell disease. Nat Rev Dis Primers 2018;4:18010. doi: 10.1038/nrdp.2018.10 [39] Angelucci E, Matthes-Martin S, Baronciani D, Bernaudin F, Bonanomi S, Cappellini MD, et al. Hematopoietic stem cell transplantation in thalassemia major and sickle cell disease: indications and management recommendations from an international expert panel. Haematologica 2014;99(5):811-20. doi: 10.3324/haematol.2013.099747 [40] Thompson AA, Walters MC, Kwiatkowski J, Rasko JEJ, Ribeil J-A, Hongeng S, et al. Gene Therapy in Patients with Transfusion-Dependent beta-Thalassemia. N Engl J Med 2018;378(16):1479-93. doi: 10.1056/NEJMoa1705342 [41] Locatelli F, Thompson AA, Kwiatkowski JL, Porter JB, Trasher AJ, Hongeng S, et al. Betibeglogene Autotemcel Gene Therapy for Non-beta(0)/beta(0) Genotype beta-Thalassemia. N Engl J Med 2021 doi: 10.1056/NEJMoa2113206 [42] Marktel S, Scaramuzza S, Cicalese MP, Giglio F, Galimberti S, Lidonnici MR, et al. Intrabone hematopoietic stem cell gene therapy for adult and pediatric patients affected by transfusion-dependent ss-thalassemia. Nat Med 2019;25(2):234-41. doi: 10.1038/ s41591-018-0301-6 [43] Ribeil JA, Hacein-Bey-Abina S, Payen E, Magnani A, Semeraro M, Magrin E, et al. Gene Therapy in a Patient with Sickle Cell Disease. N Engl J Med 2017;376(9):848-55. doi: 10.1056/NEJMoa1609677 [44] Kanter J, Walters MC, Krishnamurti L, Mapara MY, Kwiatkowski JL, Rifkin-Zenenberg S, et al. Biologic and Clinical Efficacy of LentiGlobin for Sickle Cell Disease. N Engl J Med 2022 Feb 17;386(7):617628. doi: 10.1056/NEJMoa2117175. [45] Hsieh MM, Bonner M, Pierciey FJ, Uchida N, Rottman J, Demopoulos L, et al. Myelodysplastic syndrome unrelated to lentiviral vector in a patient treated with gene therapy for sickle cell disease. Blood Adv 2020;4(9):2058-63. doi: 10.1182/bloodadvances.2019001330 [46] Goyal S, Tisdale J, Schmidt M, Kanter J, Jaroscak J, Whitney D, et al. Acute Myeloid Leukemia Case after Gene Therapy for Sickle Cell Disease. N Engl J Med 2022;386(2):138-47. doi: 10.1056/NEJMoa2109167 [47] Dever DP, Bak RO, Reinisch A, Camarena J, Washington G, Nicolas CE, et al. CRISPR/Cas9 β-globin gene targeting in human haematopoietic stem cells. Nature 2016;539(7629):384-89. doi: 10.1038/nature20134 [48] Platt FM, d'Azzo A, Davidson BL, Neufeld EF, Tifft CJ. Lysosomal storage diseases. Nat Rev Dis Primers 2018;4(1):27. doi: 10.1038/ s41572-018-0025-4 [49] Taylor M, Khan S, Stapleton M, Wang J, Chen J, Wynn R, et al. Hematopoietic Stem Cell Transplantation for Mucopolysaccharidoses: Past, Present, and Future. Biol Blood Marrow Transplant 2019;25(7):e226-e46. doi: 10.1016/j.bbmt.2019.02.012 [50] Tan EY, Boelens JJ, Jones SA, Wynn R. Hematopoietic Stem Cell Transplantation in Inborn Errors of Metabolism. Front Pediatr 2019;7:433. doi: 10.3389/fped.2019.00433 [51] Biffi A. Hematopoietic Stem Cell Gene Therapy for Storage Disease: Current and New Indications. Mol Ther 2017;25(5):1155-62. doi: 10.1016/j.ymthe.2017.03.025 [52] Eichler F, Duncan C, Musolino PL, Orchard PJ, De Oliverira S, Trasher AJ, et al. Hematopoietic Stem-Cell Gene Therapy for Cerebral Adrenoleukodystrophy. N Engl J Med 2017;377(17):1630-38. doi: 10.1056/NEJMoa1700554 [53] Keam SJ. Elivaldogene Autotemcel: First Approval. Mol Diagn Ther 2021;25(6):803-09. doi: 10.1007/s40291-021-00555-1 [published Online First: 2021/08/24] [54] Boucher AA, Miller W, Shanley R, Ziegler R, Lund T, Raymond G, et al. Long-term outcomes after allogeneic hematopoietic stem cell transplantation for metachromatic leukodystrophy: the largest single-institution cohort report. Orphanet J Rare Dis 2015;10:94. doi: 10.1186/s13023-015-0313-y [55] Fumagalli F, Calbi V, Natali Sora MG, Sessa M, Baldoli C, Rancoita PMV, et al. Lentiviral haematopoietic stem-cell gene therapy for early-onset metachromatic leukodystrophy: long-term results from a non-randomised, open-label, phase 1/2 trial and expanded access. The Lancet 2022;399(10322):372-83. doi: 10.1016/s01406736(21)02017-1 [56] Gentner B, Tucci F, Galimberti S, Fumagalli F, De Pellegrin M, Silvani P, et al. Hematopoietic Stem- and Progenitor-Cell Gene Therapy for Hurler Syndrome. N Engl J Med 2021;385(21):1929-40. doi: 10.1056/NEJMoa2106596 [published Online First: 2021/11/18] [57] Kinsella JL, Church H, Ogden W, et al. Case report of the first patient treated with ex-vivo autologous haematopoietic stem cell gene therapy transplant in mucopolysaccharidosis type IIIA. Molecular Genetics and Metabolism 2020;129(2) doi: 10.1016/j.ymgme.2019.11.225 [58] Khan A, Barber DL, Huang J, Rupar CA, Rip JW, Auray-Blais C, et al. Lentivirus-mediated gene therapy for Fabry disease. Nat Commun 2021;12(1):1178. doi: 10.1038/s41467-021-21371-5 [59] Bonini C, Ferrari G, Verzeletti S, Servida P, Zappone E, Ruggieri L, et al. HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia. Science. 1997 Jun 13;276(5319):1719-24. doi: 10.1126/science.276.5319.1719 [60] Ciceri F, Bonini C, Stanghellini MT, Bondanza A, Traversari C, Salomoni M, et al. Infusion of suicide-gene-engineered donor lymphocytes after family haploidentical haemopoietic stem-cell transplantation for leukaemia (the TK007 trial): a non-randomised phase I-II study. Lancet Oncol. 2009 May;10(5):489-500. doi: 10.1016/ S1470-2045(09)70074-9 [61] Finck AV, Blanchard T, Roselle CP, Golinelli G, June CH. Engineered cellular immunotherapies in cancer and beyond. Nat Med. 2022 Apr;28(4):678-689. doi: 10.1038/s41591-022-01765-8 [62] Morgan RA, Dudley ME, Wunderlich JR, Hughes MS, Yang JC, Sherry RM, Cancer regression in patients after transfer of genetically engineered lymphocytes. Science. 2006 Oct 6;314(5796):1269. doi: 10.1126/science.1129003 [63] Pinte L, Cunningham A, Trébéden-Negre H, Nikiforow S, Ritz J. Global Perspective on the Development of Genetically Modified Immune Cells for Cancer Therapy. Front Immunol. 2021 Feb 15;11:608485. doi: 10.3389/fimmu.2020.608485 [64] Manfredi F, Cianciotti BC, Potenza A, Tassi E, Noviello M, Biondi A, et al. TCR Redirected T Cells for Cancer Treatment: Achievements, Hurdles, and Goals. Front Immunol. 2020 Sep 3;11:1689. doi: 10.3389/fimmu.2020.01689 [65] Dever DP, Bak RO, Reinisch A, et al. CRISPR/Cas9 β-globin gene targeting in human haematopoietic stem cells. Nature 2016;539(7629):384-89. doi: 10.1038/nature20134 [66] Frangoul H, Altshuler D, Cappellini MD, et al. CRISPR-Cas9 Gene Editing for Sickle Cell Disease and β-Thalassemia. New England Journal of Medicine 2021;384(3):252-60. doi: 10.1056/NEJMoa2031054 [67] Perez EE, Wang J, Miller JC, Jouvenot Y, Kim KA, Liu O, et al. Establishment of HIV-1 resistance in CD4+ T cells by genome editing using zinc-finger nucleases. Nat Biotechnol. 2008 Jul;26(7):808-16. doi: 10.1038/nbt1410 [68] Provasi E, Genovese P, Lombardo A, Magnani Z, Liu PQ, Reik A, et al. Editing T cell specificity towards leukemia by zinc finger nucleases and lentiviral gene transfer. Nat Med. 2012 May;18(5):807815. doi: 10.1038/nm.2700 [69] Ruggiero E, Carnevale E, Prodeus A, Magnani ZI, Camisa B, Merelli I, et al. CRISPR-based gene disruption and integration of high-avidity, WT1-specific T cell receptors improve antitumor T cell function. Sci Transl Med. 2022 Feb 9;14(631):eabg8027. doi: 10.1126/ scitranslmed.abg8027
RkJQdWJsaXNoZXIy ODUzNzk5